Compare CXAIW & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAIW | XOMAO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 41 | 13 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | CXAIW | XOMAO |
|---|---|---|
| Price | $0.07 | $25.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.8K | 1.4K |
| Earning Date | 03-21-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.02 | $23.32 |
| 52 Week High | $0.16 | $25.74 |
| Indicator | CXAIW | XOMAO |
|---|---|---|
| Relative Strength Index (RSI) | 68.80 | 48.84 |
| Support Level | $0.06 | $25.16 |
| Resistance Level | $0.08 | $25.46 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 71.71 | 31.79 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.